Dr Hirsch raises important points. Pharmaceutical companies and the American Diabetes Association (ADA) continue to promote using glucose level–lowering drugs in type 2 diabetes mellitus to attain an HbA1c level below 7% despite recurring evidence of potential harm and scant evidence of benefit. Both influenced the National Committee on Quality Assurance (NCQA) to approve a performance measure for that level.1 Yet randomized clinical trials (RCTs) have not demonstrated significant benefits from glucose level–lowering agents in type 2 diabetes except for metformin. Therefore, it makes no sense for third-party payers to hold practitioners to a non–evidence-based measure of an HbA1c level below 7%.
Havas S. Treatment of Type 2 Diabetes: One Extreme to Another—Reply. Arch Intern Med. 2009;169(13):1241–1247. doi:10.1001/archinternmed.2009.187
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: